Floatz logo

T-Dxd

Brain Metastases

Iambic Therapeutics, Incantibody_drug_conjugatePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

102 Active assets in the Brain Metastases cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 4BB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 3BB
Trastuzumab Deruxtecan
Baptist Health South Florida
Phase 4BB
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB

View all 50 →

Same molecule, other indications

T-Dxd is also rated in:

HER2 positive breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →
Breast NeoplasmsDormant
B
Indicative ·
56 / 100
View asset →
estrogen-receptor positive breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →